These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 10644071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
    Das D, Lin S.
    J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
    [Abstract] [Full Text] [Related]

  • 4. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J.
    Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
    Schröder U, Sabel BA.
    Brain Res; 1996 Feb 26; 710(1-2):121-4. PubMed ID: 8963650
    [Abstract] [Full Text] [Related]

  • 7. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
    Alyaudtin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ.
    J Drug Target; 2001 Jun 26; 9(3):209-21. PubMed ID: 11697206
    [Abstract] [Full Text] [Related]

  • 8. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
    Aliautdin RN, Petrov VE, Ivanov AA, Kreuter J, Kharkevich DA.
    Eksp Klin Farmakol; 1996 Jun 26; 59(3):57-60. PubMed ID: 8974587
    [Abstract] [Full Text] [Related]

  • 9. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
    Ramge P, Kreuter J, Lemmer B.
    Chronobiol Int; 1999 Nov 26; 16(6):767-77. PubMed ID: 10584177
    [Abstract] [Full Text] [Related]

  • 10. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
    Schroeder U, Sommerfeld P, Ulrich S, Sabel BA.
    J Pharm Sci; 1998 Nov 26; 87(11):1305-7. PubMed ID: 9811481
    [Abstract] [Full Text] [Related]

  • 11. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
    Shamenkov DA, Petrov VE, Alyautdin RN.
    Bull Exp Biol Med; 2006 Dec 26; 142(6):703-6. PubMed ID: 17603675
    [Abstract] [Full Text] [Related]

  • 12. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF, Wang X, Wang C, Zhao K, Liu XJ, Shen HJ.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct 26; 31(5):732-6, 741. PubMed ID: 17062941
    [Abstract] [Full Text] [Related]

  • 13. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
    Rempe R, Cramer S, Hüwel S, Galla HJ.
    Biochem Biophys Res Commun; 2011 Mar 04; 406(1):64-9. PubMed ID: 21295549
    [Abstract] [Full Text] [Related]

  • 14. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
    Kolter M, Ott M, Hauer C, Reimold I, Fricker G.
    J Control Release; 2015 Jan 10; 197():165-79. PubMed ID: 25445700
    [Abstract] [Full Text] [Related]

  • 15. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
    Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J.
    J Microencapsul; 1998 Jan 10; 15(1):67-74. PubMed ID: 9463808
    [Abstract] [Full Text] [Related]

  • 16. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
    Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J.
    J Drug Target; 2006 Feb 10; 14(2):97-105. PubMed ID: 16608736
    [Abstract] [Full Text] [Related]

  • 17. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
    Schroeder U, Schroeder H, Sabel BA.
    Life Sci; 2000 Feb 10; 66(6):495-502. PubMed ID: 10794066
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
    Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Wang P, Ren L, Diao Y.
    Int J Nanomedicine; 2011 Feb 10; 6():445-52. PubMed ID: 21445277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.